Hyun-Woo Shin, MD, PhD

Seoul National University College of Medicine
Dpt of Pharmacology, College of Medicine
Seoul National University, Daehang-ro 101
Seoul, 41
South Korea 110744

Biographical Sketch: He received the MD degree in medicine in 2004 and the MS degree in otorhinolarygology in 2009 from Seoul National University College of Medicine, and the PhD degree in respiratory pharmacology in 2012 from Seoul National University Graduate School. From 2013 to 2014, he was appointed as a Researcher Professor at the Ischemic/Hypoxic Disease Institue, Medical Research Center, Seoul National University. Since March 2014, He has worked as an Assistant Professor at the Department of Pharmacology, Seoul National University College of Medicine and at the Department of Otorhinolarygology, Seoul National University Hospital.

His research interests focus on the pathophysiology of obstructive upper airway diseases including obstructive sleep apnea, nasal polyposis, and respiratory tumors. He endeavors to discover a novel diagnostic biomarker reflecting the hypoxic exposure, to clarify the inflammatory and biochemical mechanisms of upper airway remodeling and to identify the underlying key environments related to the epithelial origin carcinogenesis through the collaboration with diverse clinician-researchers in domestic and overseas institutes and hospitals.

Any personal financial relationships? No

I have disclosed to ICMI all relevant financial relationships, and hereby allow ICMI to disclose this information to learners in print.

I will include, as the first slide of any presentation, a full disclosure of any financial relationships that may influence my presentation.

The content and/or presentation of the information with which I am involved, including any presentation of therapeutic options, will be well-balanced, evidence-based, and will not promote specific proprietary business interests of a commercial interest. Any product identification will be made using the generic names to the extent possible. In addition, any off-label use of a medication will be specifically disclosed.

I have not and will not accept any additional honoraria, payments or reimbursements beyond that which has been agreed upon directly with ICMI.

I agree to provide educational content and resources in advance for review if requested by ICMI.

If I have been trained or utilized by a commercial entity or its agent as a speaker (e.g., speaker’s bureau) for any commercial interest, the promotional aspects of that presentation will not be included in any way with this activity.

If I am presenting research funded by a commercial company, the information presented will be based on generally accepted scientific principles and methods, and will not promote the commercial interest of the funding company.

1. I will insure balance, independence, objectivity, and scientific rigor in my role in the planning, development or presentation of this CME activity.

2. I will comply with the requirements to protect health information under the Health Insurance Portability & Accountability Act of 1996 (HIPAA).

3. I will disclose any discussion or reference to unapproved or unlabeled uses of therapeutic agents or products.

4. I have input my full name below as attestation of agreement with declaration statements. Marking the check box and indicating my name is in lieu of signature and is considered an "e-signature".

Signed on 02/10/2015 by Hyun-Woo Shin

Papers:
W.47 Epithelial Interleukin-25 Contributes to the Nasal Polypogenesis in Chronic Rhinosinusitis
W.58 SIRT1 attenuates nasal polypogenesis by suppressing HIF-1-mediated epithelial-to-mesenchymal transition

	I have disclosed to ICMI all relevant financial relationships, and hereby allow ICMI to disclose this information to learners in print.
	I will include, as the first slide of any presentation, a full disclosure of any financial relationships that may influence my presentation.
	The content and/or presentation of the information with which I am involved, including any presentation of therapeutic options, will be well-balanced, evidence-based, and will not promote specific proprietary business interests of a commercial interest. Any product identification will be made using the generic names to the extent possible. In addition, any off-label use of a medication will be specifically disclosed.
	I have not and will not accept any additional honoraria, payments or reimbursements beyond that which has been agreed upon directly with ICMI.
	I agree to provide educational content and resources in advance for review if requested by ICMI.
	If I have been trained or utilized by a commercial entity or its agent as a speaker (e.g., speaker’s bureau) for any commercial interest, the promotional aspects of that presentation will not be included in any way with this activity.
	If I am presenting research funded by a commercial company, the information presented will be based on generally accepted scientific principles and methods, and will not promote the commercial interest of the funding company.
	1. I will insure balance, independence, objectivity, and scientific rigor in my role in the planning, development or presentation of this CME activity.
	2. I will comply with the requirements to protect health information under the Health Insurance Portability & Accountability Act of 1996 (HIPAA).
	3. I will disclose any discussion or reference to unapproved or unlabeled uses of therapeutic agents or products.
	4. I have input my full name below as attestation of agreement with declaration statements. Marking the check box and indicating my name is in lieu of signature and is considered an "e-signature".